The tweet was deleted by the author.
But we saved everything 🙂.
Moderna outlined plans for the next stage of its business at its 2026 Analyst Day. The stock edges lower on the day, trading at $248.69.
Moderna outlined the next phase of growth at its 2026 Analyst Day. The company stated that more than a decade of investment in its mRNA platform has enabled the development of multiple modalities of mRNA medicines, each with the potential to create durable franchises. Moderna operates in biotechnology, employs 4,700 people and has a market value near $108.84 billion on trailing revenue of $2.52 billion.
View post on X Loading...
Price holds above its MA-20, MA-50, and MA-200, preserving a bullish daily structure despite a recent move lower. The nearest support sits at the weekly low at $237.94, and the overall chart tone remains constructive. No single technical trigger is dominating, with the price maintaining its recent trend and structure without a decisive break in either direction.
Traders should watch for a close above $280.75 to confirm buyers are willing to extend the move. Price is continuing to hold its current structure without breaking out or breaking down decisively. Even so, over the next five trading days, the probability of upside is more than 80%, while downside risk is less than 20%, with an expected trading range of $229.54 to $267.83. A drop below $237.94 would indicate the move is being faded. On the weekly chart, the longer-term picture remains firmly constructive.
Previously it was reported that Moderna's technical outlook remained constructive amid a period of elevated volatility and bullish trend conditions. The current analysis reinforces this view, with traders advised to monitor the $280.75 level as a potential pivot for further upside within the defined trading range.